Navigation Links
Cambrex Reports Third Quarter 2013 Financial Results
Date:11/1/2013

should call 1-888-510-1765 for domestic and +719-325-2494 for international.  Please use the pass code 8702967 and call approximately 10 minutes prior to start time.  A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Friday, November 8, 2013 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 8702967 to access the replay. 

About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.Forward Looking Statements
This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," including the Company's expectation that full year 2013 sales, excluding the impact of foreign currency, will increase between 9% and 12% versus 2012, that full year 2013 adjusted EBITDA will be between $64 and $68 million, that capital expenditures will be approximately $40 to $43 million, that depreciation will be $22 to $24 million in 2013, that the Company currently expects to pay only a small amount of cash taxes in the U.S. for the next few years, and that its estimated tax rate will be between 3
'/>"/>

SOURCE Cambrex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
2. Cambrex To Announce Fourth Quarter 2012 Financial Results On February 6, 2013
3. Cambrex Reports Third Quarter 2012 Financial Results
4. Cambrex to Announce Third Quarter 2012 Financial Results on October 31, 2012
5. Cambrex Announces Significant New Supply Agreement
6. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
7. Cambrex Reports First Quarter 2012 Results
8. IRIDEX Reports 2013 Third Quarter Results
9. Perrigo Reports Record First Quarter Revenue, Adjusted Earnings And Margins
10. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
11. Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
(Date:10/22/2014)... 22, 2014 At a time when ... parents and athletes at all levels, the UPMC ... the current discussion where two powerful messages are lost: ... that result in full recoveries every day. , In ... in fact and research, UPMC and the Concussion Program ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... SaaS Compliance Manager Enables PHNS and Healthcare Organizations ... ... Regulations, BATON ROUGE, La., Nov. 16 ... with PHNS, making its web-based Compliance Manager available to,hundreds of healthcare ...
... to Improved HIV Management in Developing World, UPPSALA, ... has signed an agreement with a consortium of American ... of operational,funding, and has committed to raising additional funding ... Cavidi,s newly adopted three-year,business plan. Cavidi is the producer ...
... Disclosures for Separate Account J, WASHINGTON, Nov. ... a Department of Labor investigation, launched in 2002,regarding ... of 1974 (ERISA). The Department of Labor ... pension plan, ultimately focused on whether the compensation,arrangements ...
... Sexual Behavior, Sexual Desire, ... WHAT: Are medicine and technology changing human sexuality? Does gender ... in the quality of life of people ... compelling issues on human sexuality will be the focus of ...
... HealthPartners,is the top-performing health plan in the nation ... released business report. The report, sponsored by the,National Business ... for,information tool. The tool is used by purchasers across ... Care Action Group, a coalition of,private and public employers., ...
... - December 31, TULSA, Okla., Nov. 16 ... it will offer three Medicare Part D,prescription drug plans ... Medicare. Medicare beneficiaries in Oklahoma can sign,up for or ... 2008,annual open enrollment period, which begins November 15 and ...
Cached Medicine News:Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 2Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 3Health News:New Investors Fund Expansion of Cavidi AB 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 3Health News:Charlie Rose Science Series 2Health News:HealthPartners is National Benchmark in Six Out of Seven Areas in National Business Coalition on Health Report 2Health News:Blue Cross and Blue Shield of Oklahoma Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2
... Tendril SDX is one of ... leads. Implantable with a 7 ... body diameter is designed to ... obstruction and allow introduction in ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Guidant Flextend ... transvenous pace/sense lead with ... The extendable/retractable helix design ... possibilities for permanent implantation ...
... leads are implantable bipolar extendable/retractable screw-in ... either the atrium or the ventricle. ... be extended or retracted by turning ... contains an anti-chattering mechanism for steady ...
Medicine Products: